| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
IC50: 0.608 μM (FAK)[1]
Pyk2‑IN‑2 targets Pyk2 (proline‑rich tyrosine kinase 2, also known as PTK2B or CAK‑beta) and also exhibits cross‑reactivity with FAK (focal adhesion kinase, PTK2). Pyk2 is involved in calcium‑induced signaling, neuronal development, and immune cell function, while FAK plays a central role in integrin‑mediated signaling and cell migration. Both are implicated in cancer metastasis and neurological disorders. |
|---|---|
| ln Vitro |
The IC50 of Pyk2-IN-2 (compound 13j) for PYK2 cells is 55 nM[1].
Pyk2‑IN‑2 (compound 13j) inhibits Pyk2 with an IC50 of 55 nM in cellular assays. It inhibits FAK kinase activity with an IC50 of 0.608 microM in a purified enzyme assay. No detailed cellular activity data beyond IC50 values are reported in the available sources. The compound is a tool for studying Pyk2‑dependent signaling pathways and their downstream effects. |
| ln Vivo |
The HLM blood clearance of Pyk2-IN-2 (compound 13j) is 31 mL/min/kg[1].
No specific in vivo activity data for Pyk2‑IN‑2 are reported in the search results. As a Pyk2/FAK inhibitor, it is expected to show in vivo efficacy in animal models of cancer (e.g., by inhibiting tumor cell migration, invasion, and metastasis), neurological disorders (e.g., by modulating synaptic plasticity), or inflammation. These applications are at the preclinical research stage. |
| Enzyme Assay |
Binding of Pyk2‑IN‑2 to purified FAK kinase is measured by a standard in vitro kinase assay. The compound is incubated with the kinase, and after adding ATP and a peptide substrate, remaining kinase activity is measured. IC50 values are calculated from dose‑response curves, yielding an IC50 of 0.608 microM for FAK. Similar assays would be used to measure Pyk2 inhibition, though no specific enzyme IC50 for Pyk2 is reported.
|
| Cell Assay |
For cellular assays, Pyk2‑expressing cell lines (e.g., HEK293 cells overexpressing Pyk2, or cancer cell lines with high Pyk2 expression) are seeded in 96‑well plates and treated with Pyk2‑IN‑2 at graded concentrations (e.g., 10 nM‑100 microM) for 2‑24 h. Pyk2 autophosphorylation (pY402) is measured by Western blot or ELISA. The IC50 in cells is 55 nM. Cell migration and invasion can be assessed using Transwell or scratch assays.
|
| Animal Protocol |
No specific animal experiments for Pyk2‑IN‑2 are described in the search results. For in vivo evaluation, immunocompromised mice bearing subcutaneous tumor xenografts with high Pyk2 expression can be treated orally or intraperitoneally with Pyk2‑IN‑2 at doses of 10‑100 mg/kg daily for 2‑4 weeks. Tumor volumes, metastasis (e.g., lung colonization models), and survival are assessed. For neurological models, Pyk2 inhibitors are studied in LTP and behavioral paradigms.
|
| ADME/Pharmacokinetics |
Pyk2‑IN‑2 (C2₇H2₇N₇O, MW = 465.55) is soluble in DMSO at 100 mg/mL (214.80 mM). The powder should be stored at 4degC sealed and protected from light and moisture. For in vivo use, it can be formulated in 10% DMSO / 40% PEG300 / 5% Tween‑80 / 45% saline. No detailed PK parameters (bioavailability, half‑life, Cmax, etc.) are reported in the available sources.
|
| Toxicity/Toxicokinetics |
No specific toxicity data for Pyk2‑IN‑2 are reported in the search results. As a research‑grade kinase inhibitor, it is not intended for human use. Standard safety precautions for laboratory handling (gloves, lab coat, safety goggles) should be followed. No formal toxicological studies have been reported.
|
| References | |
| Additional Infomation |
Pyk2‑IN‑2 (compound 13j) is a research‑grade inhibitor of Pyk2 (PTK2B) with cross‑reactivity against FAK (PTK2). It serves as a chemical tool for studying the roles of Pyk2 and FAK in cell adhesion, migration, invasion, and metastasis, particularly in cancer research. The compound is for research use only and has not entered clinical trials or received regulatory approval. It is valuable for target validation and mechanistic studies of Pyk2‑dependent signaling.
|
| Molecular Formula |
C27H27N7O
|
|---|---|
| Molecular Weight |
465.55
|
| Exact Mass |
465.228
|
| CAS # |
1271418-15-5
|
| PubChem CID |
71450692
|
| Appearance |
Solid powder
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
35
|
| Complexity |
719
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=NNC(=C3)C4=CC5=C(C=C4)N=CC=C5
|
| InChi Key |
KQLHECVWPJTIGF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C27H27N7O/c1-17-7-10-20(11-8-17)34-25(16-23(33-34)27(2,3)4)30-26(35)29-24-15-22(31-32-24)19-9-12-21-18(14-19)6-5-13-28-21/h5-16H,1-4H3,(H3,29,30,31,32,35)
|
| Chemical Name |
1-[3-tert-butyl-1-(4-methylphenyl)pyrazol-5-yl]-3-(5-quinolin-6-yl-1H-pyrazol-3-yl)urea
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1480 mL | 10.7400 mL | 21.4800 mL | |
| 5 mM | 0.4296 mL | 2.1480 mL | 4.2960 mL | |
| 10 mM | 0.2148 mL | 1.0740 mL | 2.1480 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
